SG11202108957RA - Fused piperidinyl bicyclic and related compounds as modulators of c5a receptor - Google Patents
Fused piperidinyl bicyclic and related compounds as modulators of c5a receptorInfo
- Publication number
- SG11202108957RA SG11202108957RA SG11202108957RA SG11202108957RA SG11202108957RA SG 11202108957R A SG11202108957R A SG 11202108957RA SG 11202108957R A SG11202108957R A SG 11202108957RA SG 11202108957R A SG11202108957R A SG 11202108957RA SG 11202108957R A SG11202108957R A SG 11202108957RA
- Authority
- SG
- Singapore
- Prior art keywords
- modulators
- receptor
- related compounds
- bicyclic
- fused
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962816726P | 2019-03-11 | 2019-03-11 | |
| EP19177349 | 2019-05-29 | ||
| US201962873612P | 2019-07-12 | 2019-07-12 | |
| PCT/EP2020/053171 WO2020182384A1 (en) | 2019-03-11 | 2020-02-07 | Fused piperidinyl bicyclic and related compounds as modulators of c5a receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202108957RA true SG11202108957RA (en) | 2021-09-29 |
Family
ID=69526272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202108957RA SG11202108957RA (en) | 2019-03-11 | 2020-02-07 | Fused piperidinyl bicyclic and related compounds as modulators of c5a receptor |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11149009B2 (ja) |
| EP (1) | EP3938351A1 (ja) |
| JP (1) | JP7360745B2 (ja) |
| KR (1) | KR20210137157A (ja) |
| CN (1) | CN113784955A (ja) |
| AU (1) | AU2020234859A1 (ja) |
| BR (1) | BR112021017756A2 (ja) |
| CA (1) | CA3129019A1 (ja) |
| CL (1) | CL2021002357A1 (ja) |
| IL (1) | IL285630A (ja) |
| MX (1) | MX2021011008A (ja) |
| PE (1) | PE20220167A1 (ja) |
| SG (1) | SG11202108957RA (ja) |
| WO (1) | WO2020182384A1 (ja) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10376595B2 (en) | 2017-04-03 | 2019-08-13 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of C5a activity |
| EP3978523A1 (en) | 2017-04-03 | 2022-04-06 | InflaRx GmbH | Treatment of inflammatory diseases with inhibitors of c5a activity |
| TW202128622A (zh) | 2019-11-08 | 2021-08-01 | 美商卡默森屈有限公司 | 補體成分C5a受體之非晶型 |
| KR20220099989A (ko) * | 2019-11-08 | 2022-07-14 | 케모센트릭스, 인크. | 보체 성분 c5a 수용체의 염 형태 |
| WO2022028586A1 (en) * | 2020-08-07 | 2022-02-10 | Kira Pharmaceuticals (Suzhou) Ltd. | Compounds as c5ar inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4704355A (en) | 1985-03-27 | 1987-11-03 | New Horizons Diagnostics Corporation | Assay utilizing ATP encapsulated within liposome particles |
| WO1991004014A1 (en) | 1989-09-21 | 1991-04-04 | Synergen, Inc. | Method for transporting compositions across the blood brain barrier |
| WO2007051062A2 (en) | 2005-10-28 | 2007-05-03 | Chemocentryx, Inc. | Substituted dihydropyridines and methods of use |
| MA32975B1 (fr) * | 2008-12-22 | 2012-01-02 | Chemocentryx Inc | Antagonistes de c5ar |
| US10376595B2 (en) | 2017-04-03 | 2019-08-13 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of C5a activity |
| EP3978523A1 (en) | 2017-04-03 | 2022-04-06 | InflaRx GmbH | Treatment of inflammatory diseases with inhibitors of c5a activity |
| CN108440514A (zh) * | 2018-05-16 | 2018-08-24 | 张玉叶 | 一种甲酰胺类衍生物、制备方法及其在抗肿瘤药物中的应用 |
| CN108558844A (zh) * | 2018-05-16 | 2018-09-21 | 张玉叶 | 一种甲酰胺类衍生物及其在抗肿瘤药物中的应用 |
| CN108727354A (zh) * | 2018-05-16 | 2018-11-02 | 张玉叶 | 一种甲酰胺类衍生物及其在抗肿瘤药物中的应用 |
| CN108440513A (zh) * | 2018-05-16 | 2018-08-24 | 张玉叶 | 一种甲酰胺类衍生物及其在抗肿瘤药物中的应用 |
| CN108727355A (zh) * | 2018-05-16 | 2018-11-02 | 张玉叶 | 一种甲酰胺类衍生物、制备方法及其在抗肿瘤药物中的应用 |
-
2020
- 2020-02-07 CA CA3129019A patent/CA3129019A1/en active Pending
- 2020-02-07 PE PE2021001484A patent/PE20220167A1/es unknown
- 2020-02-07 BR BR112021017756A patent/BR112021017756A2/pt unknown
- 2020-02-07 MX MX2021011008A patent/MX2021011008A/es unknown
- 2020-02-07 SG SG11202108957RA patent/SG11202108957RA/en unknown
- 2020-02-07 JP JP2021554679A patent/JP7360745B2/ja active Active
- 2020-02-07 KR KR1020217032491A patent/KR20210137157A/ko active Search and Examination
- 2020-02-07 US US16/784,951 patent/US11149009B2/en active Active
- 2020-02-07 EP EP20704284.7A patent/EP3938351A1/en active Pending
- 2020-02-07 CN CN202080034858.3A patent/CN113784955A/zh active Pending
- 2020-02-07 WO PCT/EP2020/053171 patent/WO2020182384A1/en unknown
- 2020-02-07 AU AU2020234859A patent/AU2020234859A1/en active Pending
-
2021
- 2021-08-15 IL IL285630A patent/IL285630A/en unknown
- 2021-09-09 CL CL2021002357A patent/CL2021002357A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN113784955A (zh) | 2021-12-10 |
| CA3129019A1 (en) | 2020-09-17 |
| BR112021017756A2 (pt) | 2021-11-16 |
| US20200290969A1 (en) | 2020-09-17 |
| AU2020234859A1 (en) | 2021-09-16 |
| US11149009B2 (en) | 2021-10-19 |
| US20210403433A1 (en) | 2021-12-30 |
| IL285630A (en) | 2021-09-30 |
| JP2022524544A (ja) | 2022-05-06 |
| MX2021011008A (es) | 2021-10-13 |
| WO2020182384A1 (en) | 2020-09-17 |
| EP3938351A1 (en) | 2022-01-19 |
| PE20220167A1 (es) | 2022-01-28 |
| KR20210137157A (ko) | 2021-11-17 |
| CL2021002357A1 (es) | 2022-04-22 |
| JP7360745B2 (ja) | 2023-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285630A (en) | Fused piperidinyl bicyclic compounds and related compounds as c5a receptor modulators | |
| IL265231B (en) | Condensed cycle inhibitors of the menin-mll interaction | |
| IL285820A (en) | Bicyclic heterocyclyl compounds and their uses | |
| IL274321A (en) | Bridged bicyclic compounds as farnesoid X receptor modulators | |
| IL287222A (en) | bicyclic compounds | |
| IL285246A (en) | Substitute bicyclic compounds as modular farnesoid x receptors | |
| IL265233A (en) | Inhibitors in the SIPO cycles of MENIN-MLL interaction | |
| HK1250710A1 (zh) | 用於製備雄激素受體拮抗劑及其中間體的方法 | |
| SG11202108796YA (en) | Substituted bicyclic compounds as farnesoid x receptor modulators | |
| IL266184B (en) | Cyclic condensed pyridine compounds and their use as ampa receptor modulators | |
| PL3613436T3 (pl) | Doustna zawiesina temozolomidu | |
| ZA202007944B (en) | Preparation of raw materials for glass furnace | |
| IL283067A (en) | Improved synthetic methods for the preparation of condensed heterocyclic compounds as orexin receptor modulators | |
| HUP1800333A2 (hu) | GABAA A5 receptor modulátor hatású biciklusos vegyületek | |
| PT3512518T (pt) | Formulações de buprenorfina de libertação prolongada | |
| IL266183B (en) | Fused azaheterocyclic compounds and their use as ampa receptor modulators | |
| IL285570A (en) | Bicyclic compounds substituted as farnesoid receptor modulators | |
| EP3491384A4 (en) | COMPOSITIONS AND METHOD FOR QUICKLY CLONING T-CELL RECEPTORS | |
| GB201916719D0 (en) | Application for safety of users | |
| EP3277665A4 (en) | Indole analogs as 5-oxo-ete receptor antagonists and method of use thereof | |
| IL270966A (en) | Fused bicyclic compounds | |
| EP3982995A4 (en) | COMPOSITIONS AND METHODS FOR INHIBITING THE BINDING OF PLASMATIC IGG AUTOANTIBODY TO THE SEROTONIN 2A RECEPTOR | |
| SG11202011378WA (en) | Synthesis of tipifarnib | |
| IL282387A (en) | Carbon of fiber cement products |